Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002254 | 0.91 | MAPK1 (0.57) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL3504393 | 0.91 | MAPK1 (0.56) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL9669207 | 0.91 | MAPK1 (0.56) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL13310355 | 0.91 | MAPK1 (0.56) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL22782306 | 0.90 | MAPT (0.70) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL17197259 | 0.90 | MAPK1 (0.54) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL17197305 | 0.90 | MAPK1 (0.54) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL31316090 | 0.90 | MAPK1 (0.54) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL16284216 | 0.88 | ABHD6 (0.55) | MAPK1KMT2AMEN1HRH3KDM4E | |
| SCHEMBL2873071 | 0.87 | MAPK1 (0.65) | MAPK1KMT2AMEN1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2543390-A1 | Pharmaceutical composition | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20110112099-A1 | THERAPEUTIC AGENT FOR CANCER RESISTANT TO PROTEASE INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112099-A1 | THERAPEUTIC AGENT FOR CANCER RESISTANT TO PROTEASE INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100098690-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100098690-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-6492387-B2 | ADMINISTERED AS AN ANTICONVULSANT AGENT, ANTIEPILEPTIC AGENT, NEUROPROTECTIVE AGENT, MUSCLE RELAXANT AGENT AND AGENT FOR THE TREATMENT OF NEUROPATHIC PAIN. | ORTHO-MCNEIL PHARAMACEUTICAL, INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1093858-C | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2002-11-06 | — | — | CN | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
| US-5610174-A | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112099-A1 | THERAPEUTIC AGENT FOR CANCER RESISTANT TO PROTEASE INHIBITOR | HSP90B1, HSP90AB1, HEATR1 | MAPK1 1287/4885KMT2A 2657/4885MEN1 4370/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | MAPK1 1765/4885KMT2A 2248/4885MEN1 92/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | MAPK1 708/4885KMT2A 3681/4885MEN1 4773/4885 |
| US-20100098690-A1 | PHARMACEUTICAL COMPOSITION | HSP90B1, HSP90AB1, HSP90AB2P | MAPK1 3337/4885KMT2A 4208/4885MEN1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.